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Association of Molecular Pathology
V.
Myriad Genetics, Inc.:
Determining the Scope of the Supreme Court's Holding
for Patentable Subject Matter
Ashley Winkle?
INTRODUCTION
Actress Angelina Jolie, famous for her sex appeal in roles like Tomb Raider and
Mr. and Mrs. Smith, sensationalized the debate surrounding diagnostic tests for
"breast cancer genes" when she shocked Americans and underwent a double
mastectomy following the results of her own test.' The important breast cancer
genes in Jolie's test were the subject of several patents issued to Myriad Genetics,
Inc., a molecular diagnostic company that isolated the sequences in 2004 and
2005.' The company's unique business practices that limited access to diagnostic
tests associated with the genes formed part of a heated national debate about the
patentability of gene sequences, resulting in dramatic headlines like "Tell Congress:
My Genes Aren't for Sale"4 or "Liberate the Breast Cancer Genes."' The United
States Supreme Court responded to some of these national cries in a recent
decision, Ass'n for Molecular Pathology v. Myriad Genetics, Inc. (hereinafter
Myriad).6 While the Court's ruling comforted some observers,
7 it also created new
'University of Kentucky College of Law, J.D. expected May 2015.
2 See Angelina Jolie, My Medical Choice, N.Y. TIMES, May 14, 2013, at A25, available at
http://www.nytimes.com/2013/OS/14/opinion/my-medical-choice.html (describing Jolie's personal
decision to have a preventative mastectomy following a diagnosis of carrying the BRCA1 gene); see also
Denise Grady et al., Jolie's Disclosure of Preventive Mastectomy Highlights Dilemma, N.Y. TIMES,
May 14, 2013, at Al, available at http://www.nytimes.com/2013/05/15/health/angelina-jolies-
disdosure-highlights-a-breast-cancer-dilemma.html (detailing the media conflict following Jolie's
public discussion of her preventative mastectomy).
See infra Part 11(b).
Sandra Fulton, Tell Congress: My Genes Aren't for Sale, AM. C.L. UNION (Apr. 27, 2010, 4:37
PM), http://www.acu.org/blog/free-speech-womens-rights/teu-congress-my-genes-arent-sale.
'Joel Engardio, Liberate the Breast Cancer Genes, AM. C.L. UNION (May 13, 2009, 8:26 AM),
http://www.aclu.org/2009/05/13/liberate-the-breast-cancer-genes; see also Ginny Graves, Who Owns
Your Genes? In Many Cases Not You, NBC NEWS (Oct. 25, 2010, 8:41 AM),
http://www.nbcnews.com/id/39335222/ns/health-cancer/#.UvPzJxa-RUQ Steven Salzberg, Myriad
Genetics CEO Claims He Owns Your Genes, FORBES (April 13, 2013, 5:24 PM),
http://www.forbes.com/sites/stevensazberg/2013/04/1
3 /myriad-genetics-ceo-owns-yur-genes.
6 133 S. Ct. 2107 (2013).
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questions about the future of biotech and other industries by reversing decades of
patent law in holding that the isolation of gene sequences is not patentable subject
matter.8 In light of the Court's opinion, the scope of the holding for determining
the patentability of current and future patent applications remains unclear.9
This Note is a reaction to the Court's decision in Myriad and argues that the
Court's holding should be narrowly interpreted. Part II of this Note outlines the
necessary background information regarding the relevant science, the state of the
law on patentable subject matter, and the important facts in the Myriad case.
Finally, Part III argues that based on factors including the technical science, the
relevant interests at play, and other agency actions external to patent law, courts
should strictly interpret and assign a narrow scope to the Court's holding against
patent eligibility for the information contained within isolated, human DNA gene
sequences.
I. BACKGROUND
Patent law is a marriage of traditional legal policy and technical science.
Consequently, in almost any question regarding patent law, in addition to studying
the legal tests, there is a need to have a basic understanding of the relevant science
underpinning the issue at bar. The case of Myriad is no different. The plausibility
and scope of the Court's decision flows directly from the Court's application of
statutory law and case law to specific biochemical facts. This section (A) outlines
the legal history of the relevant issues, (B) explains the underlying invention and
science, and (C) concludes with a summary of the legal decisions and early
consequences of Myriad.
A. Legal Development of Gene Sequences as Patentable Subject Matter
Our current patent system has broad constitutional and statutory authority
granted by Article 1, Section 8 of the United States Constitution ° and the Patent
Act of 1952.1' But despite these broad grants of authority, there remain some
limitations on patentability. To be patentable in the United States, an invention or
7 See Dan Munro, Supreme Court Breaks Myriad Monopoly, FORBES (June 16, 2013, 4:56 PM),
http://www.forbes.com/sites/danmunro/2013/06/16/supreme-court-breaks-myriad-monopoly (quoting
supporters of the Court's decision).
' Myriad changed the law established by the Supreme Court and the United States Patent and
Trademark Office. See infra Part II(a).
' See, Patrick R.H. Waller & Daniel W. Young, After the Myriad Decision: Do Hurdles Remain
for Diagnostics Competition?, MED. LABORATORY OBSERVER (Sept. 2013), http://www.mlo-
ontine.com/articles/201309/after-the-myriad-decision-do-hurdles-remain-for-diagnostics-
competition.php.
'0 See U.S. CONST. art. I, § 8 ("The Congress shall have Power .. . To promote the Progress of
Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to
their respective Writings and Discoveries ... ).
n Pub. L. No. 82-593, 66 Stat. 792 (1952) (codified at 35 U.S.C. §§1-376 (2013)).
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discovery must be eligible subject matter,12 useful,13 novel, 4 non-obvious,'" and
adequately supported in a United States patent application.
1 6
The debate regarding the patentability of gene sequences turns on the
requirement for a discovery to be patentable subject matter. Today, 35 U.S.C.
§ 101 defines the scope of patentable subject matter, providing, "[w]hoever invents
or discovers any new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof, may obtain a patent therefore,
subject to the conditions and requirements of this title." With broad constitutional
grants for patents and similarly broad statutory authority grants, the Supreme
Court has construed Congress' intent for patentable subject matter to be "anything
under the sun that is made by man."
17
Despite this broad construction, the Court imposes limits on patentable subject
matter for "laws of nature, natural phenomena, or abstract ideas." "8 These
limitations prevent minerals discovered in the earth, or even Einstein's law of
E=mc2, from being patentable because they are "manifestations of ... nature, free
to all men and reserved exclusively to none."19 The Court has acknowledged that it
must be cautious to preclude patentability due to an invention's close relationship
to nature because "all inventions at some level embody, use, reflect, rest upon, or
apply laws of nature, natural phenomena, or abstract ideas," and "too broad an
interpretation of this exclusionary principle could eviscerate patent law."2"
In Myriad, the Federal Circuit and Supreme Court relied on language from
Diamond v. Chakrabarty, which stated that "products of nature" are not patentable
subject matter.21 In Chakrabarty, the Supreme Court found that genetic alterations
in a microorganism constituted sufficient additions to nature to render the
12 35 U.S.C. § 101 (2013).
13 Id.
14 Id. § 102.
's Id. § 103.
16 Id. § 112.
" Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (citing the Committee Reports that
accompany the 1952 Act establishing modern patent law, S. REP. No. 82-1979, at 5 (1952); H.R. REP.
NO. 82-1923, at 6 (1952)). Furthermore, the Court has stated that by "choosing such expansive terms
. . . modified by the comprehensive 'any,' Congress plainly contemplated that the patent laws would be
given wide scope." Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (citing Chakrabarty, 447 U.S. at
308).
18 Mayo Collaborative Services. v. Prometheus Laboratories, Inc., 132 S. Ct. 1289, 1293 (2012)
(citing Diamond v. Diehr, 450 U.S. 175, 187 (1981)); see also Gottschalk v. Benson, 409 U.S. 63, 67
(1972) (describing unpatentable subject matter as that which arises from a mental process).
19Mayo, 132 S. Ct. at 1293 (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130
(1948)).
21 Id. (quoting Diamond v. Diehr, 450 U.S. 175, 187 (1981)) ("[A] process is not unpatentable
simply because it contains a law of nature or a mathematical algorithm.... [A]n application of a law of
nature or mathematical formula to a known structure or process may well be deserving of patent
protection.").
21 Chakrabarty, 447 U.S. at 313 ("Congress . . . recognized that the relevant distinction was not




microorganism patentable subject matter. 22 The Court took special care to
distinguish Chakrabarty from an earlier case, Funk Brothers Seed Co. v. Kalo
Inoculant Co., where the Court found that a new microorganism that merely
combined previously known bacteria already found in nature constituted
unpatentable subject matter.2 1 Specifically, the Court emphasized in Chakrabarty
that the microorganism had "markedly different characteristics from any found in
nature ... "24
Almost immediately following Chakrabarty, the United States Patent and
Trademark Office (hereinafter USPTO) demonstrated support for the Court's
holding by granting patents for DNA and gene related innovations. 25 During the
subsequent three decades, the USPTO continued to issue patents to the extent that
20% of the human genome was patented by 2005.26 In May 2010, the director of
the USPTO David Kappos summarized the historical treatment of gene sequence
patents and stated the USPTO's current position on gene sequences:
The USPTO has for decades issued patents covering isolated and purified DNA
on the scientific basis that an isolated snippet of DNA does not "exist" in nature
in the way it is claimed in patents, because naturally occurring DNA must be
isolated - that is, separated from the surrounding biological material - and
purified. Your body does not contain isolated DNA. Isolated DNA simply is not.
found in nature.27
Mr. Kappos' statement that the USPTO would continue to issue gene sequence
patents reflects decades of legal support - Supreme Court findings, consistent
USPTO interpretation, and Congress' repeated lack of action - that gene
sequences are patent-eligible subject matter.
B. Inventions and Relevant Science
The Supreme Court's holding in Myriad was based on the question of
patentability of two different types of product inventions, each related to human
gene sequences. Of these two inventions, one was held not to be patentable subject
22 Id. at 309.
23 Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 132 (1948) ("[O]nce nature's secret of
the non-inhibitive quality of certain strains of the species of Rhizobium was discovered, the state of the
art made the production of a mixed inoculant a simple step.... [WV]e conclude that the product claims
do not disclose an invention or discovery .... ).
24 Chakrabarty, 447 U.S. at 310 (emphasis added). In a more recent opinion, the Court seemingly
affirmed its requirement for a substantial change in the product of nature in order for the invention to
be patentable. Mayo, 132 S. Ct. at 1294.
25 U.S. Patent No. 4,652,525 (filed June 28, 1983); U.S. Patent No. 4,431,740 (filed June 8, 1982).
26 WENDY H. SCHACHT, CONG. RESEARCH SERV., RS 22516, GENE PATENTS: A BRIEF
OVERVIEW OF INTELLECTUAL PROPERTY ISSUES 2 & n.3 (2008) (citing Kyle Jensen & Fiona
Murray, Intellectual Property Landscape of the Human Genome, 310 SCI. MAG. 239, 239 (2005)).
27 David Kappos, Under Sec'y of Commerce for Intellectual Prop., Building Bridges and Making
Connections Across the IP System, Speech at the George Washington Law Symposium (May 11,
2010), available at http://www.uspto.gov/news/speeches/2OlO/Kappos-GWLaw_Symposium.jsp.
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matter while the other was held to be permissible patent subject matter. 
2 8
Consequently, identifying the distinctions in the two inventions is fundamental in
defining the scope of the Court's decision. The following subsections explain the
underlying science of the two inventions and also the unique practices of the
patentee.
1. Invention One: DNA and Isolated Gene Sequence.-Myriad's first series of
patent claims before the Supreme Court involved isolated sequences of human
genes called BRCA1 and BRCA2. Modern research suggests that each human has
an estimated 20,000 to 25,000 genes. 29 These genes are the "basic units of
heredity," allowing humans to transmit information to offspring.3" Furthermore,
genes work as instructions to our cells for the production of specific molecules
called proteins,31 which form the structure and define the function of human cells
and provide for the development of our bodies.
32
Genes are able to give the necessary instructions to create proteins because
genes are composed of a short section of deoxyribonucleic acid (DNA).3 3 Each
DNA molecule is arranged from four different nucleotide bases - adenine ("A"),
thymine ("T"), cytosine ("C"), and guanine ("G") - appearing in a unique, but
specific, series.34 Generally, DNA will exist in the recognizable double helix ladder:
two DNA strands that are connected through a special sugar-phosphate
backbone.3" The backbone results from each base's attraction to a complimentary
base on the opposite DNA strand, such that where A appears on the first DNA
strand, T will always appear at the same location on the second DNA strand, and a
particular chemical bond will form between them. 36 Just as A and T are
complimentary pairs, so are C and G.37 The particular order of the bases forms a
DNA sequence, and each DNA sequence then codes for a sequence of amino acids
which in turn make up a protein.
38
In humans, these gene sequences are 99.9% identical, and it is only the
remaining 0.1% that codes for differences occurring in our bodies, including
2 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111 (2013).
29 A Brief Guide to Genomics, NAT'L HUM. GENOME RES. INST., http://www.genome.gov/18016
863 (last updated Apr. 14, 2014) [hereinafter A Brief Guide to Genomics]; Mhat is a Gene?,
GENETICS HOME REF., http://ghr.nlm.nih.gov/handbook/basics/gene (last updated Sept. 29, 2014)
[hereinafter What is a Gene?].
'0 Brief for the United States as Amicus Curiae Supporting Neither Party, Ass'n of Molecular
Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cit. 2011) (No. 10-1406), 2010
WL 4853320, at *3.
31 What is a Gene?, supra note 29.
32 See A Brief Guide to Genomics, supra note 29.
33 Id.
34 Id.
35 What is DNA?, GENETICS HOME REF., http://ghr.nlm.nih.gov/handbook/basics/dna (last
updated Sept. 29, 2014).
36 Id.
37 Id.
31 Id.; A Brief Guide to Genomics, supra note 29.
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important mutations that could signal diseases or other health problems.39 The
BRCA1 and BRCA2 gene sequences are the specific series of nucleotide bases that
code for the BRCA1 and BRCA2 proteins, respectively.4" Myriad's patents include
these sequences and additionally discovered mutations or deviations from BRCA1
and BRCA2. When diagnostic testing identifies a person's gene sequence is like
the mutated, rather than normal, BRCA1 and BRCA2 gene sequences, it is
possible to predict his or her increased chance of acquiring breast or uterine
cancers.
41
The BRCA1 gene is just one sequence in a very long strand of DNA built of
many additional sequences. When combined with proteins, DNA molecules make
up complex structures called "chromosomes." 42 Every human body has forty-six
chromosomes organized in twenty-three pairs.43 Although chromosomes include
just one DNA molecule, because one DNA strand includes thousands of different
genes, one chromosome will hold millions of sequenced nucleotide bases.
Scientists have developed several different techniques for extracting DNA from
a cell and then isolating a specific gene from the DNA strand. Any of these
isolation techniques require a breaking of special bonds, called covalent bonds,
which are responsible for keeping each of the nucleotide bases of the DNA strand
connected. 44 Once the gene has been separated from the native DNA strand, it is
called "isolated DNA" or an "isolated gene sequence."4" As expected, the BRCA1
gene sequence has gone through this process of breaking covalent bonds to form a
new and chemically different molecule. 46 Scientists go through the isolation process
because the resulting gene sequence is in a form that can be used for further study
and other uses, like BRCA1 diagnostic testing, that are otherwise not possible
when the gene is part of the long DNA strand.
47
2. Invention Two: cDNA Molecules.-Myriad also has patents claiming rights to
complementary DNA (cDNA). The cDNA molecules in Myriad's claims only
include "exon," not "intron," sequences. 48 Exons code for proteins. 49 Introns appear
'9 Frequently Asked Questions about Genetic and Genomic Science, NAT'L HUM. GENOME RES.
INST., http://www.genome.gov/19016904 (last updated Feb. 14, 2014).
4 See BRCA1 and BRCA2: Cancer Risk and Genetic Testing, NAT'L CANCER INST.,
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA (last reviewed Jan. 22, 2014).
41 See id.
42 What is a Chromosome?, GENETICS HOME REF., http://ghr.nlm.nih.gov/handbook/basics/
chromosome (last updated Sept. 29, 2014).
1 What is a Gene?, TECH MUSEUM OF INNOVATION, http://genetics.thetech.org/about-
genetics/what-gene (last visited Oct. 6, 2014); A Brief Guide to Genomics, supra note 29.
"See Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303, 1328-
1330 (Fed. Cir. 2012) (explaining scientific techniques behind isolated DNA).
41 See id. at 1328.
Id. at 1329-29.
47Id. at 1341.
41 See id. at 1313-14.
4 April Cashin-Garbutt, What are Introns and Exons?, NEWS MED., http://www.news-
medical.net/hialth/What-are-introns-and-exons.aspx (last updated June 29, 2013).
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among the exons in a gene sequence, but do not have a coding function.5"
Therefore, Myriad's cDNA molecules include only the parts of the gene sequence
that are responsible for creating a specific protein. A cDNA molecule is synthesized
in a lab using messenger ribonucleic acid molecules (mRNA) as a guide for what
sequence of nucleotide bases is required.5'
An mRNA molecule results from the first step in protein creation called
transcription.5' During transcription a gene sequence is "transcribed" or copied into
ribonucleic acid (RNA). Initially, the new RNA molecule will contain both exons
and introns, but then through a process called "splicing" the introns are removed
and RNA is left only with a sequence of protein-coding exons. 53 The process of
splicing creates a molecule known as mRNA.54 Because the nucleotide bases have
complementary pairs, scientists are able to match nucleotide bases in the mRNA
sequence with their pairs."5 The resulting sequence of bases opposite mRNA forms
the nucleotide sequence in cDNA.56
cDNA technology is important to patentees, like Myriad, because by including
only the exons that code for the relevant protein, the cDNA is shorter and more
manageable for practical uses in diagnostic tests.57 The caveat, however, is that
because cDNA strands are shorter, they are easy to design around, allowing non-
patentees to practice the technology without licensing it."1 Consequently, cDNA
claims offer important protection but are less commercially productive for
patentees.
3. Patentee: Myriad Genetics, Inc.-Myriad Genetics, Inc. ("Myriad") has
employed business practices unique in pharmaceutical research, which have
generated negative media for the company and have helped to popularize the policy
concerns weighing against gene sequence patents.5 9 Myriad is a twenty-year-old
molecular diagnostic company that was initially formed to raise funds to
support genome research regarding breast cancer. 60 Pre-Myriad, government
encouragement and financial backing was insufficient to support the expensive
50 Id.
" Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303, 1313 (Fed.
Cit. 2012).
52 Id. at 1311.
53 Id.
54 Id.
5 Id. at 1313-14.
56 Id. at 1313.




s' See Johanna Jacob, Comment, Should Our Genes Be Part of the Patent Bargain? Maximizing
Access to Medical Diagnostic Advances While Ensuring Research Remains Profitable, 28 SANTA
CLARA COMPUTER & HIGH TECH. L.J. 403, 410-15 (2012).




research.6 Myriad's founders relied largely on grants from the National Institutes
of Health and significant funding by Eli Lilly and Company (hereinafter Eli
Lilly)."' Importantly, Eli Lilly was encouraged to make contributions based on
promises by Myriad to award licensing privileges to Eli Lilly for diagnostic kits and
therapeutics products.63
Myriad and associated research team members, including Eli Lilly, announced
in September 1994 that they had successfully sequenced BRCA1.64 Further
research and collaboration with a Canadian research team resulted in isolation of
the BRCA2 sequence in 1995.6" Subsequently, the USPTO issued seven patents to
Myriad regarding the BRCA1 and BRCA2 gene sequences.66
Since then, Myriad has utilized the rights granted to it through these patents.
The company quickly began administering cancer diagnostic tests with an initial
cost of $2,400, 67 growing to a cost of at least $3,000 per test in 2013. 68
Furthermore, Myriad chose an "unprecedented" business model in largely refusing
to license its patents69 and aggressively enforcing the patents by sending cease-and-
desist letters to other laboratories that were using the sequences in diagnostic
testing.7" Notably, however, the letters indicated that they were not directed to
non-commercial research activities.7 As of 2012, despite its high diagnostic prices
and monopolistic business practices, and with just three years of patent protection
61 Id. at 200-01 (stating that "[i]n 1991, the U.S. Department of Defense created a research
program devoted to breast cancer research" and that in 1990 such financial funding amounted to $90
million).
62 See E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the Policy Storm, 12
GENETICS MEDICINE S39, S41 (Apr. 2010 Supp.), available at http://www.nature.com/gim/journal/
v12/nls/full/gim2010142a.html.
63 Id. ("Because large pharmaceutical companies anticipated that genetics would produce many new
therapeutic products, Eli Lilly believed it was investing in research that might lead to a future
development of blockbuster drugs.").
64 Ass'n for Molecular Pathology v. U.S. Patent &Trademark Office, 702 F. Supp. 2d 181, 201-02
(S.D.N.Y. 2010); Yoshio Mild et. al, A Strong Candidate for the Breast and Ovarian Cancer
Susceptibility Gene BRCA1, 266 SCI. MAG. 66, 66-67 (1994).
61 See Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181,
202-03 (S.D.N.Y. 2010).
66 U.S. Patent No. 6,033,857 (filed Mar. 20, 1998); U.S. Patent No. 5,837,492 (filed Apr. 29,
1996); U.S. Patent No. 5,753,441 (filed Jan. 5, 1996); U.S. Patent No. 5,747,282 (filed June 7, 1995);
U.S. Patent No. 5,710,001 (filed June 7, 1995); U.S. Patent No. 5,709,999 (filed June 7, 1995); U.S.
Patent No. 5,693,473 (filed June 7, 1995).
67 Gold & Carbone, supra note 62, at S42.
6 Gayle Suik, Why Jolie's Cancer Test Costs So Much, CNN (May 28, 2013, 10:34 AM),
http://www.cnn.com/2013/05/24/opinion/sulik-patented-genes.
69 Olga Bograd, Comment, Patenting the Human Body: The Constitutionaity of Gene Patents
and Suggested Remedies for Reform, 63 SMU L. REV. 1319,1327 (2010).
o Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181, 187
(S.D.N.Y. 2010); see also Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d
1303, 1314-16 (Fed. Cir. 2012) (describing the various laboratories and persons which received cease-
and-desist letters from Myriad in enforcement of their patents).




remaining, Myriad had still failed to recover its steep research costs and make a
profit.
7 2
C. Legal Application and Findings in Association of
Molecular Genetics v. Myriad Genetics, Inc.
1. Lower Court Decisions.-In 2009, Plaintiffs brought suit against Myriad,
among others, in the Southern District of New York challenging the patentability
of claims relating to BRCA1 and BRCA2 in all seven of Myriad's patents.
73
Plaintiffs included the Association of Molecular Pathology, the University of
Pennsylvania together with several researchers, patient advocacy groups, and
individual patients. 74 At the trial level, the court granted Plaintiffs' summary
judgment motion on the merits, finding that the isolated DNA molecules were not
"markedly different" from native DNAs. 71 Consequently, the fifteen challenged
claims were "products of nature," constituting claims not patentable under 35
U.S.C. § 101 because of an exception to patentable subject matter created by the
Supreme Court in Chakrabarty.
76
When the case was heard by the Federal Circuit Court of Appeals, following
remand to consider the recently decided Mayo Collaborative Services v.
Prometheus Laboratories, Inc., 77 the appellate court unanimously upheld the
patentability of Myriad's claims regarding cDNA and split two to one in favor of
finding patentable subject matter regarding the isolated gene sequence claims.7"
With regard to the cDNA claims, all three judges agreed that sufficient human
contribution was made to the synthesized molecules claimed in Myriad patents,
especially where the claimed molecules did not exist in nature.
79
Myriad's patent claims over isolated BRCA1 and BRCA2 gene sequences
yielded greater debate among the court, with two judges concurring that the claims
were patentable subject matter and one judge dissenting. Judge Lourie, for the
majority, found that when native chromosomal DNA is cleaved or synthesized into
isolated DNA it becomes a distinct molecule with a chemical identity unlike native
DNA.80 The analysis particularly emphasized that covalent bonds that are broken
72 Gold & Carbone, supra note 62, at S42.
'1 Complaint at 30, Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181 (S.D.N.Y. 2010) (No. 09-CV-04515-RWS).
4 Id. at 1.
7 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181, 229
(S.D.N.Y. 2010).
76 Id. at 185, 222 (citing Diamond v. Chakrabarty, 447 U.S. 303, 309-10 (1980)).
77 132 S. Ct. 1289 (2012) (narrowing previously patentable subject matter by limiting patentability
of natural laws).
" Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303 (Fed. Cir.
2012) (upholding patentability of gene sequences and cDNA as non-naturally occurring and
invalidating Myriad method claims that were found to be abstract only).




between the isolated DNA sequence and the native DNA.8 Judge Lourie reasoned
that this chemical change creates a molecule in the isolated DNA that is different
in "name, character, and use" and thus is not a "product of nature.""2
Judge Moore concurred regarding the patentability of isolated DNA sequences.
Judge Moore recognized at least minimal chemical change in the molecule, and
even added utility for some sequences at bar, but questioned the sufficiency of the
chemical change. Nevertheless, Judge Moore reasoned that Congress' and the
USPTO's long-term support for patentability of isolated gene sequences and
purified natural substances, which have resulted in significant property rights and
expectations within the biotech industry, necessitate a finding of patentability by
the courts.
8 3
The final judge, Judge Bryson, dissented with regard to isolated DNA. Judge
Bryson questioned the sufficiency of isolation in changing the character of DNA
and emphasized the public policy concerns that necessitated a finding against
patentability. 4 Plaintiffs then petitioned for certiorari to be heard before the
United States Supreme Court, and their writ for certiorari was granted. 5
2. Supreme Court Opinion.-In an opinion written by Justice Thomas, the
Supreme Court unanimously overturned the Federal Circuit's holding regarding
the patentability of BRCA1 and BRCA2 gene sequences in finding that the
claimed gene sequences are not patentable subject matter. Regarding Myriad's
cDNA claims, however, the Court unanimously affirmed the Federal Circuit's
holding that cDNA claims are patentable subject matter. The Court held that the
isolated gene sequences BRCA1 and BRCA2 are not patentable subject matter
under 35 U.S.C. § 101.86 Notably, Justice Scalia did offer a concurrence regarding
the Court's explanation and dependence on a technical understanding of the
applicable science, stating that he was "unable to affirm those details on [his] own
knowledge or even [his] own belief.""
The Court agreed with the lower court's finding that cDNA is not a "product
of nature." Like the lower court, the Court focused on the fact that cDNA does not
occur in nature and must be synthesized in a laboratory.8 Further, the Court
countered arguments that cDNA is not patentable because cDNA's sequence is
dictated by nature, pointing out that cDNA is different from the DNA that it is
s Id. at 1329-30; see also discussion of DNA isolation techniques supra Part I(b)(1).
52 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303,1329 (citing
Diamond v. Chakrabarty, 447 U.S. 303, 309-10 (1980)).
83 Id. at 1343-48 (Moore, J., concurring in part).
Id. at 1348-55 .(Bryson, J., concurring in part and dissenting in part) (discussing the difficulty in
distinguishing nature from invention and pointing out how that difficulty affects common medical
procedures).
" Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2115-16 (2013).86 Id. at 2111.
Id. at 2120.
I Id. at 2119.
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based on and also that "the lab technician unquestionably creates something new
when cDNA is made."89 The Court, nevertheless, did caution that in the event a
cDNA strand was short enough to contain only exons, and a DNA strand of the
same length would also be composed of exons only, there may not be sufficient
difference in character to support a finding of patentable subject matter.90
In contrast to cDNA, the Court did not find sufficient human contribution to
the patent claims relating to gene sequences that would make the claims eligible as
patentable subject matter. The Court stated "[w]e ...hold that genes and the
information they encode are not patent eligible under § 101 simply because they
have been isolated from the surrounding genetic material."" In rendering its
opinion, the Court first cited to the statutory grant of patentable subject matter in
35 U.S.C. § 101,92 and immediately followed by listing the judicially created
limitations against patentable subject matter: "laws of nature, natural phenomena,
or abstract ideas."93 The Court framed the issue as determining whether, within the
traditional patent standard of weighing the need for incentives against the need for
free flow of information,94 "Myriad's patents claim any 'new and useful .. .
composition of matter,' or instead claim naturally occurring phenomena." 95 The
Court then explained that isolated gene sequences are not patentable subject matter
for three reasons: (1) Myriad merely discovered the BRCA1 and BRCA2 gene
sequences and did not invent something new; (2) Myriad's patent, taken as a
whole, was drafted reflecting the information, rather than the chemical
composition, contained in the relevant gene sequences; and (3) no deference is due
to the USPTO's practice of granting isolated gene sequence patents, especially
where Congress has never expressly supported said practice.
96
First, the Court expressly stated its view that "Myriad did not create anything"
in the isolated sequences BRCA1 and BRCA2. 7 The Court characterized
Myriad's claimed invention as merely "separating [a] gene from its surrounding
genetic material" and unequivocally found that this act was not an invention. 98 In
its analysis, the Court concentrated on the different facts in Funk Bros. Seed Co. v.
Kalo Inoculant Co., as distinguished from Diamond v. Clakrabart.99 Ultimately,
89 Id.
90 Id.
91 Id. at 2120.
92 Id. at 2116.
9' Id. (citing Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1293 (2012)).
"4 Id. (citing Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1305 (2012))
("As we have recognized before, patent protection strikes a delicate balance between creating 'incentives
that lead to creation, invention, and discovery' and 'imped[ing] the flow of information that might
permit, indeed spur, invention."').
9' Id. (internal citation omitted) (quoting 35 U.S.C. § 101 (2012)).





99 Id. at 2116-2117 (analyzing Diamond v. Chakrabarty, 447 U.S. 303 (1980); Funk Bros. Seed Co.
v. Kalo Inoculant Co., 333 U.S. 127 (1948)).
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the Court acknowledged that Myriad did find the location of the relevant genes,
but found that this "discovery" did not alone "render the BRCA genes 'new...
composition[s] of matter' that are patent eligible." 1'
Next, the Court focused its analysis on the specific language of Myriad's
patents. The Court found that Myriad neither made their patent claims based on
the chemical nature of the isolated gene sequences nor described chemical changes
that resulted from isolation.' 0' Importantly, here, the Court emphasized Myriad's
discussion of the information within the gene sequence, rather than the chemical
form, and the need for Myriad to protect the information as a way to bolster the
value of their patent.'0 2
Finally, the Court responded to arguments by Myriad and Judge Moore of the
lower court, finding that no deference was due to the USPTO practice of granting
isolated-gene-sequence patents.0 3 The Court further supported its view against
deference by pointing to an amicus curiae brief submitted to the Court by the
United States wherein the government stated its opinion that Myriad's patent
claims were not sufficiently patent eligible.'
0 4
Despite the Court's strong opinion against the patentability of Myriad isolated
gene sequence claims in BRCA1 and BRCA2, before concluding, it clearly stated
several limitations on the application of its holding.' First, because the processes
used by Myriad to actually isolate the gene sequences were common knowledge to
scientists in the field, the issue of method claims did not arise under the facts at
bar, and possible patent-eligible patent claims may exist. 106 Next, the Court
supported Judge Bryson's view and pointed out that new applications of known
isolated gene sequences may be possible."0 7 Finally, the Court expressed that its
holding does not touch instances where scientists have altered the sequence of
nucleotide bases in DNA.'
"I ld. at 2117 (internal citation omitted) (quoting 35 U.S.C. § 101 (2012)).
I51 d. at 2118 ("Nor are Myriad's claims saved by the fact that isolating DNA from the human
genome severs chemical bonds and thereby creates a nonnaturally occurring molecule. Myriad's claims
are simply not expressed in terms of chemical composition, nor do they rely in any way on the chemical
changes that result from the isolation of a particular section of DNA.").
102 Id. ("[T]he claims understandably focus on the genetic information encoded in the BRCA1 and
BRCA2 genes. If the patents depended upon the creation of a unique molecule, then a would-be
infringer could arguably avoid at least Myriad's patent claims on entire genes (such as claims 1 and 2 of
the '282 patent) by isolating a DNA sequence that included both the BRCA1 or BRCA2 gene and one
additional nucleotide pair.").
103 Id.
104 Id. at 2119.
10' Id. at 2119-20.
106 Id.




II. THE COURT'S HOLDING SHOULD BE NARROWLY CONSTRUED
Following the dramatic reversal of thirty years of patent law practice in granting
isolated gene sequence patents, it remains unclear how the Myriad holding will
immediately impact patent validity. This section seeks to outline the various
considerations that must be weighed by courts interpreting the Supreme Court's
opinion and determining its scope. This section first presents technical problems
with the Court's analysis of the technology involved; then, this section balances the
various interests that were necessarily a part of the Court's opinion. Finally, this
section points to considerations outside of patent law that will have an effect on the
success of serving the relevant interests. In conclusion, this Note argues that, based
on the foregoing factors, courts should strictly and narrowly interpret the Supreme
Court's holding in Myriad to apply only to patents of isolated human gene
sequences that seek to claim the information contained in that sequence. Further,
courts should take the Supreme Court's lead in permitting the patent eligibility of
synthesized DNA.
A. Challenges in the Court's Understanding of the Relevant Technology
Patent law is defined by the technology of an invention and the state of
knowledge of that technology at the time of an inventor's innovation or
discovery.'" 9 In fact, one requirement for patentability, obviousness, 11' measures
what would be obvious to a person skilled in the art of that technology. 1 '
Accordingly, the process of determining whether sufficient invention has occurred
for patentability's sake is grounded in an analysis of the technology.
The Supreme Court began its Myriad opinion with a description of the
technology involved. 112 There are technical errors in the Supreme Court's
explanation of the relevant science." 3 Although Justice Thomas, writing for the
majority, details some of the essential science behind gene sequencing, the Court
'o See Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89 VA. L. REV. 1575, 1579
(2003) ("Precedent set by the Supreme Court in the landmark case, Diamond v. Chakrabarty, places
with the courts the responsibility of adapting the patent statute to evolving technologies.").
11 See Id. at 1630-31 (discussing the constitutional and statutory requirements for a patent).
n 35 U.S.C. § 103 (2013).
12 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111-12 (2013).
113 Id. The Court's mistakes include mischaracterization of several concepts. For example, the Court
misnames "complementary DNA" as "composite DNA" and also overstates the role of exons in coding
for amino acids. Other associated errors and slips of terminology appear throughout the opinion. See,
e.g., Maggie Koerth-Baker, Patent Life: How the Supreme Court Fell Short, BOING BOING (July 31,
2013, 7:45 AM), http://boingboing.net/2013/07/31/patent-life-how-the-supreme-c.html; Ricki Lewis,
Genetics Errors in Supreme Court Decision, DNA SCI. BLOG (June 13, 2013), http:/iblogs.plos.org/dn
ascience/2013/06/13/genetics-errors-in-supreme-court-decision; Steven Salzberg, Supreme Court Gets





indicated in oral arguments that it did not understand the science involved.114 In
Myriad, Justice Scalia's concurrence specifically refuses to adopt the Court's
description of the technical background and expressly admits his own lack of
understanding of the science.11 The Court's analysis of the invention at bar and its
description of the science should not be used to create a limitation on patentable
subject matter or on the future of diagnostic testing.
The opposite holdings of the Federal Circuit Court of Appeals and the
Supreme Court arguably resulted from two different interpretations of the technical
field. Federal Circuit Court of Appeals Judge Lourie holds a Ph.D. in Chemistry
and was the only judge with a scientific background to hear the case.'16 Judge
Lourie focused on the breaking of covalent bonds and the difference in chemical
composition of the new, separate molecule when he found the invention was not
naturally occurring and was patent eligible. 117 Additionally, Judge Lourie
emphasized that chemically different molecules have the possibility of sharing the
same function, as in the case of Advil and ibuprofen."' In contrast, the Supreme
Court highlighted the similarity of the information, rather than the chemical
composition, in the isolated molecule as compared to native DNA."9 The Court
concluded that Myriad had focused its patents, specifically its claims, on the
unpatentable discoveries of the location of the genes and the information contained
in the genes.
121
The Court's holding against the patentability of gene sequence isolation should
be interpreted to apply only to gene sequences where the patentee attempts to claim
the information in native DNA by the way it appears in the sequence. The Court's
holding can be applied as stating that the information contained in DNA is not
patentable, in the same way that the location of a sequence is not patentable. The
Court's holding should not prevent a different patent claim where humans, in a
new and inventive way, cause a change in chemical composition, structure, or form.
"1 See Mark Joseph Stern, Scalia on DNA Patents: I Don't Really Understand the Science,
FLTrJRE TENSE (June 13, 2013, 1:43 PM), http://www.slate.com/blogs/future-tense/2013/06/13/
myriad-dna-patenting-supreme-court-case-scalia-says-he-doesn-t-get-the-science.html.
11 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2120 (2013).
116 See Courtenay C. Brinckerhoff, More on Myriad: The Chemical Divide--Judge Lourie,
PHARMAPATENTS (Aug. 4, 2011), http://www.pharmapatentsblog.com/2011/08/04/more-on-myriad-
the-chemical-divide-judge-lourie.
"1 See Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303, 1325-
33, 1336-38 (Fed. Cit. 2012).
... Id. at 1330.
9 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2120 (2013) ("'We
merely hold that genes and the information they encode are not patent eligible under [35 U.S.C.] § 101
simply because they have been isolated from the surrounding genetic material.").
120 Id. at 2117-18 ("Myriad's claims are simply not expressed in terms of chemical composition, nor




B. Balancing the Interests at Play
Allowing patent monopolies is, at its heart, a policy question. In fact, in
preparing to analyze the facts in Myriad, the Court framed the issue and standard
for the case as a balancing test in stating that "patent protection strikes a delicate
balance between creating 'incentives that lead to creation, invention, and discovery'
and 'imped[ing] the flow of information that might permit, indeed spur,
invention."'12' Consequently, as Myriad is interpreted, it should be applied in a
context considering the interests that motivated the Court to reach its holding.
1. Incentives for Medical and Pharmaceutical Research.-From the time of the
Founding Fathers through the modern Supreme Court, a primary motivating
theory for intellectual property rights is that innovation benefits society and that
the rights are necessary as incentives to encourage individuals to engage in such
innovation.'22 Certainly, advancement in medical treatment is important to society.
Unfortunately, such research and innovation comes at a very large price. In fact,
pharmaceutical research expenses in 2010 were reported to total a staggering $49
billion. 23 Under the economic theory, the monopoly resulting from the grant of a
patent provides the researcher with necessary incentive to engage in innovation,
and also may allow the researcher to recover the high costs of innovation.
124
Supporters of patenting genes argue that the isolation and research of genes and
DNA require patents in order to provide sufficient incentives for this indispensable
work and to assist research companies in regaining capital that is essential to
continued innovation.
1 25
Indeed, this kind of medical innovation has proven beneficial to many
Americans. In 2013, approximately 40,000 men and women died from breast
cancer in the United States and another 300,000 were diagnosed with the cancer.
126
121 Id. at 2116 (internal citation omitted) (quoting Mayo Collaborative Servs. v. Prometheus Labs.,
Inc., 132 S. Ct. 1289, 1305 (2012)).
122 See Burk & Lemley, supra note 109, at 1576 ("Patent law is our primary policy tool to promote
innovation, encourage the development of new technologies, and increase the fund of human
knowledge. To accomplish this end, the patent statute creates a general set of legal rules that govern a
wide variety of technologies."). Empirical studies have shown that patents do prove to be successful in
influencing research efforts. See Simone A. Rose, Patent "Monopolyphobia": A Means of Extinguishing
the Fountainhead?, 49 CASE W. RES. L. REV. 509, 509-10 (1999).
12 PHARM. RESEARCH & MFRS. OF AM., COMMENTS OF THE PHARMACEUTICAL RESEARCH
AND MANUFACTURERS OF AMERICA IN RESPONSE TO THE REQUEST FOR COMMENTS AND
NOTICE OF PUBLIC HEARINGS ON GENETIC DIAGNOSTIC TESTING 1 [hereinafter PHRMA
STUDY], available at http://www.uspto.gov/aia-implementation/gene-comment-prma.pdf
124 Alexander Tabarrok, Patent Theory Versus Patent Law, 1 CONTRIBUTIONS TO ECON.
ANALYSIS &POL'Y, Oct. 11, 2002, at 1, available athttp://mason.gmu.edu/-atabarro/PatentPublished
.pdf
12' See generally PhRMA Study, supra note 123, at 3-5 (discussing how intellectual property
protection fosters medical innovation).
126 See AM. CANCER SOC'Y, BREAST CANCER FACTS & FIGURES 2013-2014, at 4 (2013),
available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc0
4 2 7 2 5
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Nevertheless, improvements in early detection capabilities like BRCA tests and in
treatment technologies have helped to create high survival rates.127 The BRCA
genes, when detected, suggest the tested individual is at a higher risk of breast
cancer than an individual without the genes. According to one study, where
BRCA1 is detected, between 44% and 78% of women will develop breast cancer by
age 70, and where BRCA2 is detected, between 31% and 56% of women will
develop the disease. 2 s In fact, Eric Drogin, Chair of the ABA Section of Science
and Technology Law, stated that the discovery of the two genes has "open[ed] a
new chapter in the ability to individualize recommendations for a patient's care and
treatment based upon the patient's individual genetic fingerprint." 129 The BRCA
genes represent just one development resulting from medical research's growing
attention to genetic diagnostic testing. 30 Genetic testing is being researched and
used to treat everything from cancer to cardiovascular diseases, central nervous
system conditions, immunology, virology, and metabolic respiratory therapies.13 1
The intellectual property associated with medical research and other industries
additionally creates important economic factors in the balancing equation. In 2010,
patients spent an estimated $5 billion on diagnostic testing, and that number is
projected to increase to as much as $25 billion by 2021.132 Importantly, researchers
across the United States and the world spend billions of dollars each year
developing these technologies, 133 and the historically robust intellectual property
system of the United States encourages 31% of global spending on research and
development to be brought to our country.'34 The broader impact of intellectual
property rights on the economy has led innovation to be named "a primary driver of
.pdf (estimating approximately 39,620 women and approximately 410 men will die from breast cancer in
the United States in 2013).
127 Id. at 9-10 (stating that current survival rates are as high as 89% five years after diagnosis, 83%
ten years after diagnosis, and 78% fifteen years after diagnosis).
121 Id. at 12 (citing Sining Chen & Giovanni Parmigiani, Meta-analysis of BRCA1 and BRCA2
Penetrance, 25 J. CLINICAL ONCOLOGY 1329, 1329-33 (2007)). Studies vary regarding the exact risk
involved where BRCA1 or BRCA2 are detected, but all studies indicate that individuals with mutations
of the two genes do have a higher chance of developing breast cancer. See, e.g., Breast Cancer Risk
Factors You Cannot Change, AM. CANCER SOC'Y, http://www.cancer.org/cancer/breastcancer/more
information/breastcancerearlydetection/breast-cancer-early-detection-risk-factors-you-cannot-change
(last revised Sept. 10, 2014).
129 Letter from Eric Y. Drogin, Chair, Am. Bar Ass'n Section of Sci. & Tech. Law, & Robert A.
Armitage, Chair, Am. Bar Ass'n Section of Intellectual Prop. Law, to David J. Kappos, Under Sec'y of
Commerce for Intellectual Prop. & Dir. of the U.S. Patent & Trademark Office 4 (Apr. 16, 2012),
available at http://www.uspto.gov/aia implementation/gene-comment-aba.pdf.
130 See PHRMA STUDY, supra note 123.
131 Id.
132 Chad Terhune, U.S. Spending on Genetic Tests Jumps, L.A. TIMES, Mar. 12, 2012, at A14,
available at http://articles.latimes.com/2012/mar/12/business/la-fi-genetic-test-20120312.
133 See PhRMA Study, supra note 123.
"' Rod Hunter, Intellectual Property and Economic Development, TODAY'S ZAMAN (Feb. 17,
2014, 6:22 PM), http://www.todayszaman.com/news-339714-intellectual-property-and-economic-
development-by-rod-hunter.html. This is in stark contrast to India, which receives a mere 2.7% of
global research and development spending because it has weak intellectual property rights. Id.
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U.S. economic growth and national competitiveness." 3s In sum, there are strong
interests at play in favor of encouraging reasonable intellectual property rights to
exist in order to promote innovation.
2. Availability of Health care Processes to the General Public.--On the other side
of the balancing test are the costs to society in the form of exclusion from the
patented invention and the economic expense of the monopoly created by the
granted patent. In the United States, the high costs of healthcare have received
significant media attention and have been made a priority by the Obama
administration.'36 As a part of the healthcare battle, the high, even prohibitive,
costs of genetic diagnostic testing, including the Myriad BRAC analysis test at
$3,000-$4,000 per examination, received media attention.'
37 The ensuing public
debate became very one-sided in the media, with over 75% of Myriad's media
coverage being negative. 1 ' Many, including complainants against Myriad, argued
that the large price tag was a direct result of Myriad's monopoly and that the
monopoly prevented second opinions and additional research.'
39 In sum, leading up
to the Supreme Court's holding there was incredible pressure to lower the costs of
diagnostic testing by eliminating Myriad's monopoly on the test.
3. Courts Should Narrowly Apply the Supreme Court's Opinion.-Ultimately, the
pressure to lower the cost of healthcare and the public outcry for increased
availability to these diagnostic tests likely motivated the Court to find against
patentability. From the late 1980s to the early 2000s when most gene sequence
patents were granted, the state of molecular biology was much different than it is
today, and there was an international call for incentives to map the human
13s ECON. & STATISTICS ADMIN. & U.S. PATENT & TRADEMARK OFFICE, INTELLECTUAL
PROPERTY AND THE U.S. ECONOMY: INDUSTRIES IN FOCUS, at v (Mar. 2012), available at
http://www.esa.doc.gov/sites/default/fles/reports/dcuments/ipandtheuseconmyindustriesinfocus.pdf.
13 See generally Healthcare Reform Tops Obama's Priority List, PBS NEWSHOUR (June 8, 2009,
12:30 PM), http://www.pbs.org/newshour/updates/health-jan-june09-healthpreview_- 
0 6-08 (discussing
the White House's intentions to aggressively approach health care reform); The Obama-Biden Plan,
CHANGE.GOV, http://change.gov/agenda/health-care.agenda (last visited Oct. 8, 2014) (explaining
the proposed Obama-Biden plan for health care reform).
137 See, e.g., David B. Agus, Op-Ed., The Outrageous Cost ofa Gene Test, N.Y. TIMES, May 21,
2013, at A25, available at http://www.nytimes.com/2013/05/21/opinion/the-outrageous-cost-of-a-
gene-test.html; Sulik, supra note 68.
13 Timothy Caulfield et al., Myriad and the Mass Media: The Covering of a Gene Patent
Controversy, 9 GENETICS MEDICINE 850, 852-53 (2007), available at http://www.nature.com/gini/
joumal/v9/n12/pdf/gim2007l26a.pdf.
139 See Complaint at 2, 18-19, 25-26, Ass'n for Molecular Pathology v. U.S. Patent & Trademark
Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (No. 1:09-cv-04515-RWS), 2009 WL 1343027
(describing individual complainants' interest in the litigation and presenting arguments about the
failures caused by the Myriad patent); see also Agus, supra note 137; Courtenay C. Brinckerhoff,





genome. 4 ° Contrastingly, today, the methods used for isolation and even for
discovery that were instituted by Myriad's scientists have become commonplace
and accepted in the field.' Modern scientists are now charged with developing
new ways of using gene sequences to better and more cost-efficiently diagnose,
prevent, and treat diseases and other medical conditions. The Court's ruling
promotes public interests in favor of accessible gene sequence testing, but it does
not eliminate the need to offer incentives for improved use of the sequences.
Therefore, courts should apply the ruling as merely foreclosing patentability of
identical genetic information like that present in the Myriad patent claims.
Largely, the emphasis on public policy concerns points to the Court's role as a
gatekeeper of the public interest and not an analyzer of technical science. Even the
Court was careful to limit the scope of its opinion to product or composition claims
where information was the target for the patent claims involved. 142 A necessary
function of patents in biotechnology is to encourage researchers to invest resources
by providing a mechanism to recoup those costs and potentially make a profit.
Attempts to extend the holding to limit isolation from patentability could
undermine this purpose. Many areas of medicine, like antibiotics, that necessarily
flow from nature are already facing decreasing research.143 Because of the continued
need for antibiotics, 144 an interpretation that would prevent protection of
antibiotics would strip away necessary incentives. The Court's holding specifically
targets identical information in product claims, and its scope should be reasonably
limited with this in mind.
The Court specifically endorsed the patentability of synthesized DNA, even
where the function of the synthesized DNA is the same as naturally-occurring
DNA. 141 Consequently, courts should focus on human contribution and invention
in the field of molecular biology and allow claims for lab-created molecules, even in
the event they act like or look like natural DNA.
4. Additional Opportunities to Balance Outlying Issues.-While it is true that the
patent system flows from balancing incentives within a given technology and
especially within the biotech arena, patent law and the USPTO are not the only
necessary considerations. Supporters of the action brought against Myriad
applauded the Court's holding and argue that it should be broadly construed and
140 See An Overview of the Human Genome Project, NAT'L HUM. GENOME RES. INST. (last
reviewed Nov. 8, 2012), http://www.genome.gov/12011238.
"' See Daniel Fisher, Supreme Court Rejects Human-Gene Patents - Sort Of, FORBES (June 13,
2013, 11:06 AM), http://www.forbes.com/sites/danielfisher/2013/06/13/supreme-court-rejects-human-
gene-patents-sort-of (describing the reluctance by the USPTO to grant gene sequence patents in view
of modern scientific knowledge).
142 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119-20 (2013).
143 See Eben Harrell, The Desperate Need for New Antibiotics, TIME (Oct. 1, 2009),
http://content.time.com/time/health/artide/0,8599,1926853,00.html.
" Id. (describing the failure of researchers to invest in needed antibiotics, largely because of low
profitability, and suggesting that increased patent incentives are needed).
145 See Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119 (2013).
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applied. 46 However, these arguments often fail to account for resources external to
the patent system that can address Myriad's bad practices. Some problems, like
Myriad's anti-competitive attitude and aggressive enforcement tactics, arise outside
the scope of patent law and should not prevent the validity of patents issued to
deserving inventors who developed unique ways to test genetic material.
A common-law research exception is used in some jurisdictions to allow non-
commercial research uses of patented technology without infringement.
14 7 Recall
that in the cease-and-desist letter Myriad sent, the research exception was
referenced when the letter indicated that it did not target non-commercial research
activities.148 However, the exception is narrow and typically only provides for de
minimis use of the patented invention. 49 Expanded adoption of this exception in
more jurisdictions or statutorily by Congress could bolster the goals of patent law
by encouraging additional research on patented technology while still protecting
the inventor's economic interests.
The research exception is supported by the requirement that patent applicants,
in return for the possibility of a limited monopoly, are required to disclose their
invention to the extent that a person skilled in the art could copy or recreate 
it. 50
Patent theory suggests that such a disclosure requirement encourages invention
beyond already discovered information.'' Realization of the goal of innovation
supports the research exception because through the exception researchers are able
to increase knowledge more efficiently.'5 2 Researchers are able to learn more,
" See, e.g., Emily Bazelon, Patently Unfair, SLATE (June 13, 2013, 2:51 PM),
http://www.slate.com/articles/news-and-pofitics/jurisprudence/2013/06/clarence-thomas-opinion-on-
myriad-genetics-the-supreme court_ruled unanimously.html; Dan Munro, supra note 7.
117 Madey v. Duke Univ., 307 F.3d 1351, 1355, 1361 (Fed. Cit. 2002).
148 See description of the cease-and-desist letters sent by Myriad to laboratories and other entities
supra Part I(b)(3); see also Ass'n of Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 187 (S.D.N.Y. 2010).
"' See Denise W. DeFranco et al., The Experimental Use Exception: Looking Towards a
Legislaive Alternative, 6J. HIGH TECH. L. 93,94 (2006).
150 35 U.S.C. § 112(a) (2013). In the United States Patent Office, most patent applications will be
published and publicly available eighteen months after filing, even if the application never results in
patent protection for the applicant. § 122(b)(1).
15' See Note, The Disclosure Function of the Patent System (or Lack Thereof), 118 HARV. L. REV.
2007, 2009 (2005) ("[T]he information disclosed in the patent theoretically produces three distinct
benefits for the public: helping spur further innovation, reducing wasteful duplicative research, and
leading to more efficient investment in innovation.").
152 In fact, under this theory, the research exception has been largely adopted in foreign patent
systems. See EVANS MISATI & KIYOSHI ADACHI, THE RESEARCH AND EXPERIMENTATION
EXCEPTIONS IN PATENT LAW: JURISDICTIONAL VARIATIONS AND THE WIPO DEVELOPMENT
AGENDA, (2010), available at http://unctad.org/en/Docs/iprs-in20102en.pdf (quoting WORLD
TRADE ORG., WT/DS114/R, CANADA - PATENT PROTECTION OF PHARMACEUTICAL PRODUCTS
165, at 7.69 (2000), available at http://www.wto.org/english/tratop-e/dispu e/7428d.pdf) ("'[A] key
public policy purpose underlying patent laws is to facilitate the dissemination and advancement of
technical knowledge and that allowing the patent owner to prevent experimental use during the term of
the patent would frustrate part of the purpose of the requirement that the nature of the invention be
disclosed to the public."').
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without increasing their research costs, through purchasing licenses or otherwise
being prohibited from pursuing their research until the twenty-year patent lapses.
Patented inventors, however, are still motivated to innovate because they still
receive a commercial monopoly in any patented invention they create.
Myriad's uncommon failure to license also led to an unavailability of "second
opinions" because Myraid was the only company able to administer the test. 153 A
number of options external to the USPTO exist to combat this practice. While
uncommon, in instances of a public health crisis, governments are able to require
"compulsory licensing" of a patented technology.'54 The United States has been
willing to impose compulsory licenses in the past. 5 5 Accordingly, compulsory
licenses remain an option for the courts, and, in reaction to Myriad's bad practices,
courts should not dramatically change validity analyses to decrease patent
protections that encourage research and development throughout the United
States.'56
Additionally, prior to the filing of Myriad, the Food and Drug Administration
("FDA") announced its intention to begin regulating diagnostic testing. 5 7 The
FDA is responsible for advancing public health5 8 and even tracks its origin to a
close relationship with the USPTO. 159 The FDA is poised to take on specific
challenges with diagnostic testing, and to establish industry practices to support
availability and reliability for United States patients.
CONCLUSION
The social contract between inventors, society, and the United States
government has motivated Congress to grant limited monopolies to inventors
against the public's interest in freely exercising a technology for the sake of
encouraging innovation and, therefore, to benefit the public's overall breadth of
knowledge. This balance became dramatic when the patent involved key cancer
technology that tested a patient's own DNA, and restricted testing to just one
1s3 See Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S.Ct. 2107, 2113-14 (2013).
154 See Joanna Thurston et al., Compulsory Licenses: Necessity or Threat?, CHEMISTRY WORLD
(May 23, 2013), http://www.rsc.org/chemistryworld/2013/05/compulsory-icence-license-patent-dmgs-
debate (discussing the international agreement to limit compulsory licenses and their ability to be
employed by international governments).
5s See US Leads the World in Use of Compulsory Licenses: KEI, ECON. TIMES (Mar. 20,2014,
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provider - the patentee. The Supreme Court balanced several interests and found
that mere isolation of gene sequences is an insufficient contribution as to require
the public to give up its rights to accessibility, and now courts must apply the
Myriad opinion. Where decades of patent practice and important technical
knowledge in the art are relevant, courts must additionally apply public policy and
law to the pertinent science. In order to best ensure the sustainability of the biotech
industry for public healthcare, the Court's holding against the patentability of
isolated, human DNA gene sequences should be narrowly construed. Lower courts
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